With the wide application of immune checkpoint inhibitors (ICIs) in the treatment of NSCLC, programmed cell death protein 1 (PD‐1), and programmed death‐ligand 1 (PD‐L1) antibodies have been reported to improve survival to varying degrees in NSCLC patients with KRAS mutations,19, 20 both chemo‐naïve and chemorefractory. Here, KRAS is linked to non-small cell lung carcinoma.